The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes

被引:86
作者
Bowalgaha, K
Miners, JO [1 ]
机构
[1] Flinders Med Ctr, Dept Clin Pharmacol, Bedford Pk, SA 5042, Australia
[2] Flinders Univ S Australia, Bedford Pk, SA 5042, Australia
关键词
glucuronidation; human tissue; intrinsic clearance; mycophenolic acid;
D O I
10.1046/j.0306-5251.2001.01487.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims To estimate the relative contribution of liver, kidney and jejunum to MPA elimination via glucuronidation from in vitro kinetic data. Methods The kinetics of MPA glucuronidation by human liver, kidney and jejunum microsomes were characterized. Mycophenolic acid glucuronide (MPAG) concentrations in microsomal incubations were determined using a specific h.p.l.c. procedure. Non-specific microsomal binding of MPA was excluded using an equilibrium dialysis approach. Results Microsomes from all three tissues catalysed the conversion of MPA to MPAG. Mean microsomal intrinsic clearances for MPAG formation by liver, kidney and jejunum microsomes were 46.6, 73.5 and 24.5 mul (min mg)(-1), respectively. When extrapolated to the whole organ, however, hepatic intrinsic clearance was 21- and 38-fold higher than the respective intrinsic clearances for kidney and small intestine. Conclusions The data suggest that the liver is the organ primarily responsible for the systemic clearance of MPA, with little contribution from the kidney, and that the small intestine would be expected to contribute to first-pass extraction to a minor extent only.
引用
收藏
页码:605 / 609
页数:5
相关论文
共 13 条
[1]  
AITIO A, 1976, ACTA PHARMACOL TOX, V39, P555
[2]   Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration [J].
Bullingham, R ;
Monroe, S ;
Nicholls, A ;
Hale, M .
JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 36 (04) :315-324
[3]   Clinical pharmacokinetics of mycophenolate mofetil [J].
Bullingham, RES ;
Nicholls, AJ ;
Kanmm, BR .
CLINICAL PHARMACOKINETICS, 1998, 34 (06) :429-455
[4]  
HOUSTON JB, 1994, BIOCHEM PHARMACOL, V47, P1469
[5]   Identification of uridine diphosphate glucuronosyltransferases involved in the metabolism and clearance of mycophenolic acid [J].
Mackenzie, PI .
THERAPEUTIC DRUG MONITORING, 2000, 22 (01) :10-13
[6]   Nonspecific binding of drugs to human liver microsomes [J].
McLure, JA ;
Miners, JO ;
Birkett, DJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 49 (05) :453-461
[7]   The human UDP glucuronosyltransferase, UGT1A10, glucuronidates mycophenolic acid [J].
Mojarrabi, B ;
Mackenzie, PI .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 238 (03) :775-778
[8]  
PAINE MF, 1997, J PHARMACOL EXP THER, V283, P46
[9]   CHARACTERIZATION OF THEOPHYLLINE METABOLISM IN HUMAN-LIVER MICROSOMES [J].
ROBSON, RA ;
MATTHEWS, AP ;
MINERS, JO ;
MCMANUS, ME ;
MEYER, UA ;
HALL, PD ;
BIRKETT, DJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 24 (03) :293-300
[10]   Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil [J].
Shipkova, M ;
Armstrong, VW ;
Wieland, E ;
Niedmann, PD ;
Schütz, E ;
Brenner-Weiss, G ;
Voihsel, M ;
Braun, F ;
Oellerich, M .
BRITISH JOURNAL OF PHARMACOLOGY, 1999, 126 (05) :1075-1082